Keywords: UK, NICE, Celgen, Janssen, Talidomide, Velcade, Myeloma, USA, FDA, Istodax, Lymphoma

UK NICE backing for Celgene and Janssen multiple myeloma drugs, Thalidomide and Velcade; FDA fast-tracks Istodax sNDA

Article | 20 June 2011

Print This

In final draft guidance published on Friday, UK drug watchdog the National Institute for Health and Clinical Excellence (NICE) recommends ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in